{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:18:17Z","timestamp":1785161897850,"version":"3.55.0"},"reference-count":251,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.prp.2024.155636","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T15:49:04Z","timestamp":1727970544000},"page":"155636","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Recent update on anti-tumor mechanisms of valproic acid in glioblastoma multiforme"],"prefix":"10.1016","volume":"263","author":[{"given":"Abulfazl","family":"Vatankhah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepehr Hoseinzadeh","family":"Moghaddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadaf","family":"Afshari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir R.","family":"Afshari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kesharwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1124\/pr.117.014944","article-title":"Current challenges and opportunities in treating glioblastoma","volume":"70","author":"Shergalis","year":"2018","journal-title":"Pharmacol. Rev."},{"issue":"4","key":"10.1016\/j.prp.2024.155636_bib2","first-page":"299","article-title":"Management of glioblastoma: state of the art and future directions","volume":"70","author":"Tan","year":"2020","journal-title":"CA: A Cancer J. Clin."},{"key":"10.1016\/j.prp.2024.155636_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103625","article-title":"Advantages and drawbacks of dexamethasone in glioblastoma multiforme","volume":"172","author":"Afshari","year":"2022","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"11","key":"10.1016\/j.prp.2024.155636_bib4","doi-asserted-by":"crossref","first-page":"18577","DOI":"10.18632\/oncotarget.14612","article-title":"Advances in epigenetic glioblastoma therapy","volume":"8","author":"Lee","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2024.155636_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.562798","article-title":"Current opinion on molecular characterization for GBM classification in guiding clinical diagnosis, prognosis, and therapy","volume":"7","author":"Zhang","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.prp.2024.155636_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00879","article-title":"Glioblastoma Treatments: An account of recent industrial developments","volume":"9","author":"Alphand\u00e9ry","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.prp.2024.155636_bib7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jnci.2016.07.001","article-title":"Management of glioblastoma after recurrence: a changing paradigm","volume":"28","author":"Mallick","year":"2016","journal-title":"J. Egypt. Natl. Cancer Inst."},{"issue":"9","key":"10.1016\/j.prp.2024.155636_bib8","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1016\/S1470-2045(14)70011-7","article-title":"EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma","volume":"15","author":"Weller","year":"2014","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.prp.2024.155636_bib9","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/jhg.2017.91","article-title":"The pharmacogenomics of valproic acid","volume":"62","author":"Zhu","year":"2017","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.prp.2024.155636_bib10","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/479364","article-title":"Molecular and therapeutic potential and toxicity of valproic acid","volume":"2010","author":"Chateauvieux","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.prp.2024.155636_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1033035","article-title":"Cross-reactivity between histone demethylase inhibitor valproic acid and DNA methylation in glioblastoma cell lines","volume":"12","author":"Barciszewska","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib12","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1602\/neurorx.2.1.54","article-title":"Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems","volume":"2","author":"Tsuji","year":"2005","journal-title":"NeuroRX"},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s12185-008-0226-9","article-title":"Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma","volume":"89","author":"Kitazoe","year":"2009","journal-title":"Int. J. Hematol."},{"issue":"10","key":"10.1016\/j.prp.2024.155636_bib14","doi-asserted-by":"crossref","DOI":"10.5812\/ircmj.37230","article-title":"Comparison of Anticancer Effects of Carbamazepine and Valproic Acid","volume":"18","author":"Akbarzadeh","year":"2016","journal-title":"Iran. Red. Crescent Med. J."},{"issue":"2","key":"10.1016\/j.prp.2024.155636_bib15","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.lungcan.2013.08.010","article-title":"Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines","volume":"82","author":"Shirsath","year":"2013","journal-title":"Lung Cancer"},{"issue":"14","key":"10.1016\/j.prp.2024.155636_bib16","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.3390\/cancers13143409","article-title":"Valproic acid and breast cancer: state of the art in 2021","volume":"13","author":"Wawruszak","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.prp.2024.155636_bib17","first-page":"1795","article-title":"Valproic acid and interferon-\u03b1 synergistically inhibit neuroblastoma cell growth in vitro and in vivo","volume":"25","author":"Michaelis","year":"2004","journal-title":"Int. J. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib18","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1210\/jc.2004-1355","article-title":"Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells","volume":"90","author":"Catalano","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.prp.2024.155636_bib19","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1158\/1535-7163.MCT-05-0184","article-title":"Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC","volume":"4","author":"Li","year":"2005","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib20","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ctrv.2007.11.003","article-title":"Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors","volume":"34","author":"Duenas-Gonzalez","year":"2008","journal-title":"Cancer Treat. Rev."},{"issue":"14","key":"10.1016\/j.prp.2024.155636_bib21","doi-asserted-by":"crossref","first-page":"7237","DOI":"10.1158\/0008-5472.CAN-05-0487","article-title":"Chronic Administration of Valproic Acid Inhibits Prostate Cancer Cell Growth In vitro and In vivo","volume":"66","author":"Xia","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2024.155636_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.687362","article-title":"Valproic acid: a promising therapeutic agent in glioma treatment","volume":"11","author":"Han","year":"2021","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.prp.2024.155636_bib23","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s12032-014-0985-5","article-title":"Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience","volume":"31","author":"Bezecny","year":"2014","journal-title":"Med. Oncol."},{"issue":"7","key":"10.1016\/j.prp.2024.155636_bib24","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3390\/ijms18071414","article-title":"Histone Deacetylase Inhibitors as Anticancer Drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2024.155636_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.645518","article-title":"Sodium valproate-induced chromatin remodeling","volume":"9","author":"Mello","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"4","key":"10.1016\/j.prp.2024.155636_bib26","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1158\/1535-7163.MCT-08-1076","article-title":"Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo","volume":"8","author":"Kortenhorst","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.prp.2024.155636_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216125","article-title":"Valproate and lithium: Old drugs for new pharmacological approaches in brain tumors?","volume":"560","author":"Natale","year":"2023","journal-title":"Cancer Lett."},{"issue":"39","key":"10.1016\/j.prp.2024.155636_bib28","doi-asserted-by":"crossref","first-page":"62989","DOI":"10.18632\/oncotarget.11379","article-title":"Molecular dissection of the valproic acid effects on glioma cells","volume":"7","author":"Hoja","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.prp.2024.155636_bib29","first-page":"535","article-title":"Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells","volume":"30","author":"Papi","year":"2010","journal-title":"Anticancer Res."},{"issue":"10","key":"10.1016\/j.prp.2024.155636_bib30","doi-asserted-by":"crossref","first-page":"e1435-e","DOI":"10.1038\/cddis.2014.412","article-title":"Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe","volume":"5","author":"Cornago","year":"2014","journal-title":"Cell death Dis."},{"issue":"2","key":"10.1016\/j.prp.2024.155636_bib31","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00432-019-03118-4","article-title":"Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes","volume":"146","author":"Kiweler","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.prp.2024.155636_bib32","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/6326053","article-title":"The effect of sodium valproate on the glioblastoma U87 cell line tumor development on the chicken embryo chorioallantoic membrane and on EZH2 and p53 expression","volume":"2017","author":"Kavaliauskait\u0117","year":"2017","journal-title":"BioMed. Res. Int."},{"issue":"2","key":"10.1016\/j.prp.2024.155636_bib33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-007-9402-7","article-title":"Valproic acid induces p21 and topoisomerase-II (\u03b1\/\u03b2) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines","volume":"85","author":"Das","year":"2007","journal-title":"J. Neuro-Oncol."},{"issue":"9","key":"10.1016\/j.prp.2024.155636_bib34","doi-asserted-by":"crossref","first-page":"14666","DOI":"10.18632\/oncotarget.14716","article-title":"Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression","volume":"8","author":"Tseng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2024.155636_bib35","article-title":"HDAC inhibitor valproic acid increases CRABP2 expression and in combination with retinoic acid synergistically inhibits proliferation in glioblastoma cells","author":"Yao","year":"2016","journal-title":"doctoralThesis"},{"issue":"2","key":"10.1016\/j.prp.2024.155636_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211644","article-title":"AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro","volume":"14","author":"Lange","year":"2019","journal-title":"PLOS ONE"},{"issue":"5","key":"10.1016\/j.prp.2024.155636_bib37","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/neuonc\/nov238","article-title":"Prognostic relevance of epilepsy at presentation in glioblastoma patients","volume":"18","author":"Berendsen","year":"2016","journal-title":"Neuro-Oncol."},{"issue":"4","key":"10.1016\/j.prp.2024.155636_bib38","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/med.20027","article-title":"Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studies","volume":"25","author":"Blaheta","year":"2005","journal-title":"Med. Res. Rev."},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib39","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/1471-2407-10-383","article-title":"Cell type-specific anti-cancer properties of valproic acid: independent effects on HDAC activity and Erk1\/2 phosphorylation","volume":"10","author":"Gotfryd","year":"2010","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.prp.2024.155636_bib40","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/bjc.2013.21","article-title":"Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair","volume":"108","author":"Groselj","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.prp.2024.155636_bib41","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3390\/ph16020227","article-title":"Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy","volume":"16","author":"Everix","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib42","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.pharmthera.2014.04.004","article-title":"Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights","volume":"143","author":"Bose","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.prp.2024.155636_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119504","article-title":"Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy","volume":"277","author":"Ramaiah","year":"2021","journal-title":"Life Sci."},{"issue":"4","key":"10.1016\/j.prp.2024.155636_bib44","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1158\/1535-7163.MCT-08-0985","article-title":"HDAC2 regulates chromatin plasticity and enhances DNA vulnerability","volume":"8","author":"Marchion","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.prp.2024.155636_bib45","doi-asserted-by":"crossref","first-page":"46","DOI":"10.20517\/2347-8659.2018.58","article-title":"Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma","volume":"5","author":"Yelton","year":"2018","journal-title":"Neuroimmunol. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib46","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1158\/0008-5472.CAN-03-0799","article-title":"Histone Deacetylase Is a Target of Valproic Acid-Mediated Cellular Differentiation","volume":"64","author":"Gurvich","year":"2004","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.prp.2024.155636_bib47","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/1078-0432.CCR-08-1930","article-title":"Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I\/II trial of valproic acid and epirubicin\/FEC","volume":"15","author":"Munster","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"39","key":"10.1016\/j.prp.2024.155636_bib48","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.prp.2024.155636_bib49","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1158\/0008-5472.CAN-04-2478","article-title":"Valproic acid alters chromatin structure by regulation of chromatin modulation proteins","volume":"65","author":"Marchion","year":"2005","journal-title":"Cancer Res."},{"issue":"24","key":"10.1016\/j.prp.2024.155636_bib50","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"G\u00f6ttlicher","year":"2001","journal-title":"EMBO J."},{"issue":"10","key":"10.1016\/j.prp.2024.155636_bib51","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1097\/CAD.0b013e32835739dd","article-title":"Valproic acid shows potent antitumor effect with alteration of DNA methylation in neuroblastoma","volume":"23","author":"Gu","year":"2012","journal-title":"Anti-Cancer Drugs"},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib52","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1868-7083-5-12","article-title":"Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents","volume":"5","author":"Fredly","year":"2013","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.prp.2024.155636_bib53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cbi.2017.12.003","article-title":"Valproic acid, a histone deacetylase inhibitor, induces apoptosis in breast cancer stem cells","volume":"280","author":"Aztopal","year":"2018","journal-title":"Chem. -Biol. Interact."},{"issue":"8b","key":"10.1016\/j.prp.2024.155636_bib54","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1111\/j.1582-4934.2008.00436.x","article-title":"The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo","volume":"13","author":"Jones","year":"2009","journal-title":"J. Cell. Mol. Med."},{"issue":"2","key":"10.1016\/j.prp.2024.155636_bib55","first-page":"248","article-title":"The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma","volume":"91","author":"Kaiser","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.prp.2024.155636_bib56","doi-asserted-by":"crossref","unstructured":"Catalano M.G., Fortunati N., Pugliese M., Poli R., Bosco O., Mastrocola R., et al. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. Journal of Endocrinology.191(2):465-472.","DOI":"10.1677\/joe.1.06970"},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib57","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2478\/acph-2020-0021","article-title":"Anticonvulsant valproic acid and other short-chain fatty acids as novel anticancer therapeutics: possibilities and challenges","volume":"70","author":"Lipska","year":"2020","journal-title":"Acta Pharm."},{"issue":"2","key":"10.1016\/j.prp.2024.155636_bib58","first-page":"95","article-title":"The Effects of apoptosis and the cell cycle arresting of valproate and nicotinamide on U87 Cell Line","volume":"5","author":"Jafary","year":"2019","journal-title":"Biomacromolecular J."},{"issue":"12","key":"10.1016\/j.prp.2024.155636_bib59","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.3390\/biomedicines9121749","article-title":"Synergistic anticancer effect of glycolysis and histone deacetylases inhibitors in a glioblastoma model","volume":"9","author":"Paj\u0105k","year":"2021","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.prp.2024.155636_bib60","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1002\/jcb.26512","article-title":"Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors","volume":"119","author":"Tarasenko","year":"2018","journal-title":"J. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib61","article-title":"Effects of valproic acid on histone deacetylase inhibition in vitro and in glioblastoma patient samples","volume":"1","author":"Berendsen","year":"2019","journal-title":"Neuro-Oncol. Adv."},{"issue":"9","key":"10.1016\/j.prp.2024.155636_bib62","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1517\/13543784.2012.694425","article-title":"Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results","volume":"21","author":"Berendsen","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib63","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2174\/157488708785700320","article-title":"Chromatin remodeling agents for cancer therapy","volume":"3","author":"Dario","year":"2008","journal-title":"Rev. Recent Clin. Trials"},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib64","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bbcan.2011.12.004","article-title":"O6-Methylguanine-DNA methyltransferase in glioma therapy: Promise and problems","volume":"1826","author":"Silber","year":"2012","journal-title":"Biochim. Et. Biophys. Acta (BBA) - Rev. Cancer"},{"issue":"6","key":"10.1016\/j.prp.2024.155636_bib65","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/jnc.14326","article-title":"Transcriptional control of O 6 -methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma","volume":"144","author":"Happold","year":"2018","journal-title":"J. Neurochem."},{"issue":"10","key":"10.1016\/j.prp.2024.155636_bib66","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2176\/nmc.ra.2018-0141","article-title":"Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma","volume":"58","author":"Jiapaer","year":"2018","journal-title":"Neurol. Med. -Chir."},{"issue":"10","key":"10.1016\/j.prp.2024.155636_bib67","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.prp.2024.155636_bib68","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00381-021-05278-6","article-title":"Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling","volume":"38","author":"Kresbach","year":"2022","journal-title":"Child'S. Nerv. Syst."},{"key":"10.1016\/j.prp.2024.155636_bib69","article-title":"Valproic Acid Downregulates the Expression of MGMT and Sensitizes Temozolomide-Resistant Glioma Cells","volume":"2012","author":"Ryu","year":"2012","journal-title":"BioMed. Res. Int."},{"key":"10.1016\/j.prp.2024.155636_bib70","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.biochi.2019.08.003","article-title":"Role of AKT and mTOR signaling pathways in the induction of epithelial-mesenchymal transition (EMT) process","volume":"165","author":"Roshan","year":"2019","journal-title":"Biochimie"},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib71","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nrm3758","article-title":"Molecular mechanisms of epithelial\u2013mesenchymal transition","volume":"15","author":"Lamouille","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib72","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/abbs\/gmx123","article-title":"TGF-\u03b2 signaling in cancer metastasis.","volume":"50","author":"Xie","year":"2018","journal-title":"Acta Biochim. Et. Biophys. Sin."},{"key":"10.1016\/j.prp.2024.155636_bib73","article-title":"Valproic acid inhibits glioma and its mechanisms","volume":"2022","author":"Yang","year":"2022","journal-title":"J. Healthc. Eng."},{"issue":"10","key":"10.1016\/j.prp.2024.155636_bib74","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.3390\/biomedicines9101328","article-title":"Cadherin expression and EMT: a focus on gliomas","volume":"9","author":"Noronha","year":"2021","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.prp.2024.155636_bib75","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3390\/biomedicines12071416","article-title":"Differential impact of valproic Acid on SLC5A8, SLC12A2, SLC12A5, CDH1, and CDH2 expression in adult glioblastoma cells","volume":"12","author":"Juknevi\u010dien\u0117","year":"2024","journal-title":"Biomedicines"},{"issue":"12","key":"10.1016\/j.prp.2024.155636_bib76","first-page":"2737","article-title":"Regulation and role of post-translational modifications of enhancer of zeste homologue 2 in cancer development","volume":"6","author":"Lu","year":"2016","journal-title":"Am. J. Cancer Res."},{"issue":"1, Part 2","key":"10.1016\/j.prp.2024.155636_bib77","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.gene.2015.09.080","article-title":"Functional roles of enhancer of zeste homolog 2 in gliomas","volume":"576","author":"Yin","year":"2016","journal-title":"Gene"},{"issue":"2, Part B","key":"10.1016\/j.prp.2024.155636_bib78","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.canlet.2014.11.003","article-title":"EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma","volume":"356","author":"Zhang","year":"2015","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.prp.2024.155636_bib79","first-page":"6662","article-title":"Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma","volume":"7","author":"Fan","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"9","key":"10.1016\/j.prp.2024.155636_bib80","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3390\/cancers10090297","article-title":"The p53 pathway in glioblastoma","volume":"10","author":"Zhang","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2024.155636_bib81","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.biocel.2017.10.003","article-title":"The synergistic effects of valproic acid and fluvastatin on apoptosis induction in glioblastoma multiforme cell lines","volume":"92","author":"Chang","year":"2017","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"4","key":"10.1016\/j.prp.2024.155636_bib82","first-page":"334","article-title":"Cytotoxic effects of auraptene against a human malignant glioblastoma cell line","volume":"9","author":"Afshari","year":"2019","journal-title":"Avicenna J. phytomedicine"},{"issue":"22","key":"10.1016\/j.prp.2024.155636_bib83","doi-asserted-by":"crossref","first-page":"5672","DOI":"10.3390\/ijms20225672","article-title":"The Anti-Tumorigenic Activity of Sema3C in the Chick Embryo Chorioallantoic Membrane Model","volume":"20","author":"Valiulyt\u0117","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.prp.2024.155636_bib84","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11060-014-1713-x","article-title":"The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells","volume":"122","author":"Hosein","year":"2015","journal-title":"J. Neuro-Oncol."},{"issue":"33","key":"10.1016\/j.prp.2024.155636_bib85","doi-asserted-by":"crossref","first-page":"35004","DOI":"10.18632\/oncotarget.5253","article-title":"Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells","volume":"6","author":"Thotala","year":"2015","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.prp.2024.155636_bib86","first-page":"453","article-title":"Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines","volume":"16","author":"Ciusani","year":"2007","journal-title":"Oncol. Res. Featur. Preclin. Clin. Cancer Ther."},{"issue":"5A","key":"10.1016\/j.prp.2024.155636_bib87","first-page":"3585","article-title":"Valproic acid inhibits proliferation and changes expression of CD44 and CD56 of malignant glioma cells in vitro","volume":"18","author":"Kn\u00fcpfer","year":"1998","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.prp.2024.155636_bib88","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1159\/000485753","article-title":"Cellular Effects of the Antiepileptic Drug Valproic Acid in Glioblastoma","volume":"44","author":"Eckert","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib89","doi-asserted-by":"crossref","first-page":"207","DOI":"10.21873\/anticanres.13099","article-title":"Combined Applications of Repurposed Drugs and Their Detrimental Effects on Glioblastoma Cells","volume":"39","author":"Sachkova","year":"2019","journal-title":"Anticancer Res."},{"issue":"8","key":"10.1016\/j.prp.2024.155636_bib90","doi-asserted-by":"crossref","first-page":"6816","DOI":"10.1007\/s12035-018-0895-1","article-title":"Combination Therapy with Sulfasalazine and Valproic Acid Promotes Human Glioblastoma Cell Death Through Imbalance of the Intracellular Oxidative Response","volume":"55","author":"Garcia","year":"2018","journal-title":"Mol. Neurobiol."},{"issue":"12","key":"10.1016\/j.prp.2024.155636_bib91","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/carcin\/bgz069","article-title":"Phospho-valproic acid (MDC-1112) suppresses glioblastoma growth in preclinical models through the inhibition of STAT3 phosphorylation","volume":"40","author":"Luo","year":"2019","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib92","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3390\/cancers6010376","article-title":"STAT3 Activation in Glioblastoma: Biochemical and Therapeutic Implications","volume":"6","author":"Kim","year":"2014","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib93","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11060-016-2056-6","article-title":"The effects of antiepileptic drugs on the growth of glioblastoma cell lines","volume":"127","author":"Lee","year":"2016","journal-title":"J. Neuro-Oncol."},{"issue":"12","key":"10.1016\/j.prp.2024.155636_bib94","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1093\/neuonc\/nou147","article-title":"Targeting adaptive glioblastoma: an overview of proliferation and invasion","volume":"16","author":"Xie","year":"2014","journal-title":"Neuro-Oncol."},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib95","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s13287-020-01703-w","article-title":"Intracellular functions of RNA-binding protein, Musashi1, in stem and cancer cells","volume":"11","author":"Forouzanfar","year":"2020","journal-title":"Stem Cell Res. Ther."},{"issue":"10","key":"10.1016\/j.prp.2024.155636_bib96","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1200\/JCO.2005.03.089","article-title":"Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis","volume":"23","author":"Lefranc","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2024.155636_bib97","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.semcancer.2019.04.001","article-title":"Emerging role of PI3K\/AKT in tumor-related epigenetic regulation","volume":"59","author":"Yang","year":"2019","journal-title":"Semin. Cancer Biol."},{"issue":"5","key":"10.1016\/j.prp.2024.155636_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2020.118659","article-title":"GSK-3\u03b2 in DNA repair, apoptosis, and resistance of chemotherapy, radiotherapy of cancer","volume":"1867","author":"Lin","year":"2020","journal-title":"Biochim. Et. Biophys. Acta (BBA) - Mol. Cell Res."},{"issue":"2","key":"10.1016\/j.prp.2024.155636_bib99","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbcan.2013.07.001","article-title":"Invasion as target for therapy of glioblastoma multiforme","volume":"1836","author":"Vehlow","year":"2013","journal-title":"Biochim. Et. Biophys. Acta (BBA) - Rev. Cancer"},{"issue":"5","key":"10.1016\/j.prp.2024.155636_bib100","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0736-5748(99)00010-6","article-title":"Matrix metalloproteinases and their biological function in human gliomas","volume":"17","author":"Chintala","year":"1999","journal-title":"Int. J. Dev. Neurosci."},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2015.03.015","article-title":"Mechanisms regulating glioma invasion","volume":"362","author":"Paw","year":"2015","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.prp.2024.155636_bib102","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.canlet.2009.12.006","article-title":"Suberoylanilide hydroxamic acid limits migration and invasion of glioma cells in two and three dimensional culture","volume":"292","author":"An","year":"2010","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib103","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11060-012-0871-y","article-title":"Valproic acid affected the survival and invasiveness of human glioma cells through diverse mechanisms","volume":"109","author":"Chen","year":"2012","journal-title":"J. Neuro-Oncol."},{"issue":"10","key":"10.1016\/j.prp.2024.155636_bib104","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.3390\/cells10102509","article-title":"ERK: a double-edged sword in cancer. ERK-dependent apoptosis as a potential therapeutic strategy for cancer","volume":"10","author":"Sugiura","year":"2021","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.prp.2024.155636_bib105","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/A:1023043315031","article-title":"novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling","volume":"22","author":"Noda","year":"2003","journal-title":"Cancer Metastas-.-. Rev."},{"key":"10.1016\/j.prp.2024.155636_bib106","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.toxrep.2014.05.005","article-title":"In vitro anticancer drug test: a new method emerges from the model of glioma stem cells","volume":"1","author":"Riva","year":"2014","journal-title":"Toxicol. Rep."},{"key":"10.1016\/j.prp.2024.155636_bib107","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2015.00152","article-title":"Reconciling the discrepancies on the involvement of large-conductance Ca2+-activated K channels in glioblastoma cell migration","volume":"9","author":"Catacuzzeno","year":"2015","journal-title":"Front. Cell. Neurosci."},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncb3452","article-title":"The control of DNA repair by the cell cycle","volume":"19","author":"Hustedt","year":"2017","journal-title":"Nat. Cell Biol."},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib109","first-page":"48","article-title":"Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions","volume":"3","author":"Juric","year":"2020","journal-title":"Cancer Drug Resist."},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2174\/156800908783497131","article-title":"Inhibitors of Cyclin Dependent Kinases: Useful Targets for Cancer Treatment","volume":"8","author":"Sharma","year":"2008","journal-title":"Curr. Cancer Drug Targets"},{"issue":"6","key":"10.1016\/j.prp.2024.155636_bib111","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrc2657","article-title":"p21 in cancer: intricate networks and multiple activities","volume":"9","author":"Abbas","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib112","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/PPO.0b013e31803c72ba","article-title":"Histone deacetylase inhibitors: biology and mechanism of action","volume":"13","author":"Mehnert","year":"2007","journal-title":"Cancer J."},{"issue":"2","key":"10.1016\/j.prp.2024.155636_bib113","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3181\/00379727-213-44046","article-title":"p21\u2014negative regulator of the cell cycle. proceedings of the society for","volume":"213","author":"Gartel","year":"1996","journal-title":"Exp. Biol. Med."},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib114","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/15384101.2014.1000134","article-title":"Senescence from G2 arrest, revisited","volume":"14","author":"Gire","year":"2015","journal-title":"Cell Cycle"},{"issue":"10","key":"10.1016\/j.prp.2024.155636_bib115","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.leukres.2007.03.012","article-title":"Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia","volume":"31","author":"Cheng","year":"2007","journal-title":"Leuk. Res."},{"issue":"6","key":"10.1016\/j.prp.2024.155636_bib116","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.3892\/ijo.2015.3213","article-title":"Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation","volume":"47","author":"Mawatari","year":"2015","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2024.155636_bib117","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s13277-010-0126-5","article-title":"The G1 phase arrest and apoptosis by intrinsic pathway induced by valproic acid inhibit proliferation of BGC-823 gastric carcinoma cells","volume":"32","author":"Zhao","year":"2011","journal-title":"Tumor Biol."},{"key":"10.1016\/j.prp.2024.155636_bib118","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.722754","article-title":"Valproic Acid Enhanced Temozolomide-Induced Anticancer Activity in Human Glioma Through the p53\u2013PUMA Apoptosis Pathway","volume":"11","author":"Tsai","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib119","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1186\/s12885-019-5843-6","article-title":"Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells","volume":"19","author":"Chen","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib120","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1748-717X-9-89","article-title":"Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines","volume":"9","author":"Rubner","year":"2014","journal-title":"Radiat. Oncol. (Lond., Engl. )"},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib121","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev-cancerbio-050216-121933","article-title":"Apoptosis and Cancer","volume":"1","author":"Letai","year":"2017","journal-title":"Annu. Rev. Cancer Biol."},{"issue":"12","key":"10.1016\/j.prp.2024.155636_bib122","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.trecan.2017.10.006","article-title":"Mitochondria, bioenergetics and apoptosis in cancer","volume":"3","author":"Burke","year":"2017","journal-title":"Trends Cancer"},{"issue":"16","key":"10.1016\/j.prp.2024.155636_bib123","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.18632\/oncotarget.28031","article-title":"Interactions of multidomain pro-apoptotic and anti-apoptotic proteins in cancer cell death","volume":"12","author":"Chota","year":"2021","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2024.155636_bib124","doi-asserted-by":"crossref","DOI":"10.1177\/0963689720981878","article-title":"Valproic acid enhanced apoptosis by promoting autophagy via Akt\/mTOR signaling in glioma","volume":"29","author":"Han","year":"2020","journal-title":"Cell Transplant."},{"issue":"4","key":"10.1016\/j.prp.2024.155636_bib125","doi-asserted-by":"crossref","first-page":"392","DOI":"10.4103\/1735-5362.350240","article-title":"The effect of valproic acid on intrinsic, extrinsic, and JAK\/STAT pathways in neuroblastoma and glioblastoma cell lines","volume":"17","author":"Sanaei","year":"2022","journal-title":"Res. Pharm. Sci."},{"issue":"12","key":"10.1016\/j.prp.2024.155636_bib126","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/sj.cdd.4401130","article-title":"Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe","volume":"9","author":"Castedo","year":"2002","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.prp.2024.155636_bib127","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/B978-0-12-407695-2.00007-X","article-title":"Role of cyclin B1 levels in DNA damage and DNA damage-induced senescence","volume":"305","author":"Nakayama","year":"2013","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"10.1016\/j.prp.2024.155636_bib128","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.canlet.2018.11.019","article-title":"Cyclin B1\/CDK1-regulated mitochondrial bioenergetics in cell cycle progression and tumor resistance","volume":"443","author":"Xie","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2024.155636_bib129","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.dnarep.2018.07.008","article-title":"Multiple functions of p27 in cell cycle, apoptosis, epigenetic modification and transcriptional regulation for the control of cell growth: A double-edged sword protein","volume":"69","author":"Abbastabar","year":"2018","journal-title":"DNA Repair"},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib130","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00280-007-0619-0","article-title":"Combination of all-trans retinoic acid and interferon-gamma upregulated p27kip1 and down regulated CDK2 to cause cell cycle arrest leading to differentiation and apoptosis in human glioblastoma LN18 (PTEN-proficient) and U87MG (PTEN-deficient) cells","volume":"62","author":"Zhang","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.prp.2024.155636_bib131","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3390\/antiox10020256","article-title":"Human paraoxonase-2 (PON2): Protein functions and modulation","volume":"10","author":"Manco","year":"2021","journal-title":"Antioxidants"},{"issue":"6","key":"10.1016\/j.prp.2024.155636_bib132","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1159\/000447912","article-title":"Valproic acid promotes human glioma U87 cells apoptosis and inhibits glycogen synthase kinase-3\u03b2 through ERK\/Akt signaling","volume":"39","author":"Zhang","year":"2016","journal-title":"Cell. Physiol. Biochem."},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib133","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00109-010-0707-1","article-title":"Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation","volume":"89","author":"Chen","year":"2011","journal-title":"J. Mol. Med. (Berl., Ger. )"},{"key":"10.1016\/j.prp.2024.155636_bib134","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.semcancer.2020.08.002","article-title":"Effects of statins on brain tumors: a review","volume":"73","author":"Afshari","year":"2021","journal-title":"Semin Cancer Biol."},{"issue":"8","key":"10.1016\/j.prp.2024.155636_bib135","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s10571-020-00930-2","article-title":"Valproic acid sensitizes glioma cells to luteolin through induction of apoptosis and autophagy via akt signaling","volume":"41","author":"Han","year":"2021","journal-title":"Cell. Mol. Neurobiol."},{"issue":"12","key":"10.1016\/j.prp.2024.155636_bib136","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1007\/s11064-011-0554-7","article-title":"Valproic acid induced differentiation and potentiated efficacy of taxol and nanotaxol for controlling growth of human glioblastoma LN18 and T98G Cells","volume":"36","author":"Roy Choudhury","year":"2011","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.prp.2024.155636_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113740","article-title":"Recent advances in glioblastoma multiforme therapy: a focus on autophagy regulation","volume":"155","author":"Sanati","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.prp.2024.155636_bib138","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.572904","article-title":"Therapeutic potential of autophagy in glioblastoma treatment with phosphoinositide 3-kinase\/protein kinase B\/mammalian target of rapamycin signaling pathway inhibitors","volume":"10","author":"Xia","year":"2020","journal-title":"Front. Oncol."},{"issue":"22","key":"10.1016\/j.prp.2024.155636_bib139","doi-asserted-by":"crossref","first-page":"33440","DOI":"10.18632\/oncotarget.7961","article-title":"PI3K\/Akt\/mTOR signaling pathway and targeted therapy for glioblastoma","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"issue":"23","key":"10.1016\/j.prp.2024.155636_bib140","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.2174\/138161211797249224","article-title":"Targeting the AKT pathway in glioblastoma","volume":"17","author":"A McDowell","year":"2011","journal-title":"Curr. Pharm. Des."},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib141","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.3390\/ijms22031318","article-title":"Deciphering the role of autophagy in treatment of resistance mechanisms in glioblastoma","volume":"22","author":"Khan","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.prp.2024.155636_bib142","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3390\/ijms18091865","article-title":"Monitoring and measuring autophagy","volume":"18","author":"Yoshii","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib143","doi-asserted-by":"crossref","first-page":"305","DOI":"10.4161\/cbt.27309","article-title":"HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells","volume":"15","author":"Booth","year":"2014","journal-title":"Cancer Biol. Ther."},{"issue":"11","key":"10.1016\/j.prp.2024.155636_bib144","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/iub.1445","article-title":"Valproic acid sensitizes human glioma cells to gefitinib-induced autophagy","volume":"67","author":"Chang","year":"2015","journal-title":"IUBMB Life"},{"issue":"34","key":"10.1016\/j.prp.2024.155636_bib145","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1038\/onc.2010.221","article-title":"New insights into apoptosis signaling by Apo2L\/TRAIL","volume":"29","author":"Gonzalvez","year":"2010","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.prp.2024.155636_bib146","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3390\/biom11040572","article-title":"Overcoming TRAIL Resistance for Glioblastoma Treatment","volume":"11","author":"Deng","year":"2021","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib147","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3892\/or.2021.7937","article-title":"Combination treatment with VPA and MSCs\u2011TRAIL could increase anti\u2011tumor effects against intracranial glioma","volume":"45","author":"Park","year":"2021","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.prp.2024.155636_bib148","article-title":"The dual role of the CD95 and CD95L signaling pathway in glioblastoma","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.prp.2024.155636_bib149","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/ijc.33698","article-title":"key protein of cross-talk signal way in \u201cPANoptosis\u201d in cancer","volume":"149","author":"Jiang","year":"2021","journal-title":"Int. J. Cancer"},{"issue":"44","key":"10.1016\/j.prp.2024.155636_bib150","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1038\/onc.2011.614","article-title":"Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP","volume":"31","author":"Bangert","year":"2012","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.prp.2024.155636_bib151","first-page":"174","article-title":"Valproic acid regulates the miR-155\/Jarid2 axis by affecting miR-155 promoter methylation in glioma","volume":"56","author":"Wang","year":"2024","journal-title":"Acta Biochim Biophys. Sin. (Shanghai)"},{"issue":"5","key":"10.1016\/j.prp.2024.155636_bib152","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s12035-020-01892-8","article-title":"Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma","volume":"57","author":"Ahir","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.prp.2024.155636_bib153","doi-asserted-by":"crossref","DOI":"10.1017\/S1462399408000768","article-title":"New molecular targets in angiogenic vessels of glioblastoma tumours","volume":"10","author":"Anderson","year":"2008","journal-title":"Expert Rev. Mol. Med."},{"issue":"10","key":"10.1016\/j.prp.2024.155636_bib154","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1200\/JCO.2014.55.9575","article-title":"Lessons From Anti\u2013Vascular Endothelial Growth Factor and Anti\u2013Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma","volume":"33","author":"Lu-Emerson","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.prp.2024.155636_bib155","doi-asserted-by":"crossref","first-page":"8502","DOI":"10.1073\/pnas.93.16.8502","article-title":"Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor","volume":"93","author":"Cheng","year":"1996","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.prp.2024.155636_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.jff.2022.105192","article-title":"Targeting angiogenesis in gliomas: potential role of phytochemicals","volume":"96","author":"Sanati","year":"2022","journal-title":"J. Funct. Foods"},{"issue":"4","key":"10.1016\/j.prp.2024.155636_bib157","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2176\/nmc.52.186","article-title":"Valproic Acid Inhibits Angiogenesis In Vitro and Glioma Angiogenesis In Vivo in the Brain","volume":"52","author":"Osuka","year":"2012","journal-title":"Neurol. Med. -Chir."},{"issue":"5","key":"10.1016\/j.prp.2024.155636_bib158","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.hoc.2004.06.002","article-title":"Epidermal growth factor receptor in tumor angiogenesis","volume":"18","author":"Ellis","year":"2004","journal-title":"Hematol. \/Oncol. Clin."},{"issue":"7","key":"10.1016\/j.prp.2024.155636_bib159","first-page":"2585","article-title":"Temozolomide and treatment of malignant glioma1","volume":"6","author":"Friedman","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib160","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1874467211205010102","article-title":"Temozolomide: Mechanisms of Action, Repair and Resistance","volume":"5","author":"Zhang","year":"2012","journal-title":"Curr. Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib161","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.gendis.2016.04.007","article-title":"Temozolomide resistance in glioblastoma multiforme","volume":"3","author":"Lee","year":"2016","journal-title":"Genes Dis."},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib162","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/bmb\/ldm036","article-title":"O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy","volume":"85","author":"Verbeek","year":"2008","journal-title":"Br. Med. Bull."},{"issue":"30","key":"10.1016\/j.prp.2024.155636_bib163","doi-asserted-by":"crossref","first-page":"27586","DOI":"10.1074\/jbc.M303740200","article-title":"Valproate Induces Replication-independent Active DNA Demethylation","volume":"278","author":"Detich","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib164","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-011-0725-z","article-title":"Valproic acid sensitizes human glioma cells for temozolomide and \u03b3-radiation","volume":"107","author":"Van Nifterik","year":"2012","journal-title":"J. neuro-Oncol."},{"issue":"6","key":"10.1016\/j.prp.2024.155636_bib165","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1007\/s11064-011-0701-1","article-title":"Drug resistance in glioblastoma: a mini review","volume":"37","author":"Haar","year":"2012","journal-title":"Neurochem. Res."},{"issue":"14","key":"10.1016\/j.prp.2024.155636_bib166","doi-asserted-by":"crossref","first-page":"12452","DOI":"10.18632\/oncotarget.3611","article-title":"SEL1L SNP rs12435998, a predictor of glioblastoma survival and response to radio-chemotherapy","volume":"6","author":"Mellai","year":"2015","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.prp.2024.155636_bib167","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.freeradbiomed.2009.07.035","article-title":"Nrf2:INrf2 (Keap1) signaling in oxidative stress","volume":"47","author":"Kaspar","year":"2009","journal-title":"Free Radic. Biol. Med."},{"issue":"5","key":"10.1016\/j.prp.2024.155636_bib168","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.3390\/jcm9051562","article-title":"Heme oxygenase-1 in central nervous system malignancies","volume":"9","author":"Sferrazzo","year":"2020","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.prp.2024.155636_bib169","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41390-019-0628-9","article-title":"Musashi1 enhances chemotherapy resistance of pediatric glioblastoma cells in vitro","volume":"87","author":"P\u00f6tschke","year":"2020","journal-title":"Pediatr. Res."},{"issue":"5","key":"10.1016\/j.prp.2024.155636_bib170","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/biology10050407","article-title":"Musashi\u20131\u2014A Stemness RBP for Cancer Therapy?","volume":"10","author":"Bley","year":"2021","journal-title":"Biology"},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib171","first-page":"899","article-title":"Adaptive Immune Response to and Survival Effect of Temozolomide- and Valproic Acid-induced Autophagy in Glioblastoma","volume":"36","author":"Proske","year":"2016","journal-title":"Anticancer Res."},{"key":"10.1016\/j.prp.2024.155636_bib172","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.semcdb.2014.01.005","article-title":"Amphiregulin","volume":"28","author":"Berasain","year":"2014","journal-title":"Semin. Cell Dev. Biol."},{"issue":"2","key":"10.1016\/j.prp.2024.155636_bib173","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bbcan.2011.05.003","article-title":"The multiple roles of amphiregulin in human cancer","volume":"1816","author":"Busser","year":"2011","journal-title":"Biochim. Et. Biophys. Acta (BBA) - Rev. Cancer"},{"issue":"2","key":"10.1016\/j.prp.2024.155636_bib174","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3390\/cancers14020443","article-title":"Tumor cell infiltration into the brain in glioblastoma: from mechanisms to clinical perspectives","volume":"14","author":"Seker-Polat","year":"2022","journal-title":"Cancers"},{"issue":"13","key":"10.1016\/j.prp.2024.155636_bib175","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/glia.20856","article-title":"Amphiregulin is a factor for resistance of glioma cells to cannabinoid-induced apoptosis","volume":"57","author":"Lorente","year":"2009","journal-title":"Glia"},{"issue":"1-2","key":"10.1016\/j.prp.2024.155636_bib176","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ijpharm.2018.08.039","article-title":"Valproate sensitizes human glioblastoma cells to 3-bromopyruvate-induced cytotoxicity","volume":"551","author":"Ishiguro","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib177","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/cancers11030317","article-title":"Tumor energy metabolism and potential of 3-bromopyruvate as an inhibitor of aerobic glycolysis: implications in tumor treatment","volume":"11","author":"Fan","year":"2019","journal-title":"Cancers"},{"issue":"18","key":"10.1016\/j.prp.2024.155636_bib178","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.2174\/092986710791163939","article-title":"Riluzole, neuroprotection and amyotrophic lateral sclerosis","volume":"17","author":"Cheah","year":"2010","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib179","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/fcp.12712","article-title":"Antidepressants with anti-tumor potential in treating glioblastoma: a narrative review","volume":"36","author":"Abadi","year":"2022","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.prp.2024.155636_bib180","doi-asserted-by":"crossref","DOI":"10.1200\/PO.18.00282","article-title":"Prolonged partial response to bevacizumab and valproic acid in a patient with glioblastoma","author":"Fountzilas","year":"2018","journal-title":"JCO Precis. Oncol."},{"issue":"6","key":"10.1016\/j.prp.2024.155636_bib181","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/MPH.0b013e3181d74702","article-title":"Sorafenib plus valproic acid for infant spinal glioblastoma","volume":"32","author":"Rokes","year":"2010","journal-title":"J. Pediatr. Hematol. \/Oncol."},{"issue":"5","key":"10.1016\/j.prp.2024.155636_bib182","article-title":"The HDAC inhibitors scriptaid and lbh589 combined with the oncolytic virus Delta24-RGD exert enhanced anti-tumor efficacy in patient-derived glioblastoma cells","volume":"10","author":"Pont","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.prp.2024.155636_bib183","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.addr.2015.05.009","article-title":"Progress and problems with the use of suicide genes for targeted cancer therapy","volume":"99","author":"Karjoo","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib184","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.bbrc.2012.04.050","article-title":"Valproic acid enhances anti-tumor effect of mesenchymal stem cell mediated HSV-TK gene therapy in intracranial glioma","volume":"421","author":"Ryu","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib185","first-page":"1","article-title":"Gap junctions and Bystander effects: Good Samaritans and executioners","volume":"2","author":"Spray","year":"2013","journal-title":"Wiley Interdiscip. Rev.: Membr. Transp. Signal."},{"key":"10.1016\/j.prp.2024.155636_bib186","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.canlet.2018.10.043","article-title":"Connexin 43 (Cx43) in cancer: Implications for therapeutic approaches via gap junctions","volume":"442","author":"Bonacquisti","year":"2019","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib187","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3390\/cancers13030580","article-title":"Molecular and metabolic mechanisms underlying selective 5-aminolevulinic acid-induced fluorescence in gliomas","volume":"13","author":"Traylor","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.prp.2024.155636_bib188","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s11910-014-0517-x","article-title":"The value of extent of resection of glioblastomas: clinical evidence and current approach","volume":"15","author":"Almeida","year":"2015","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib189","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11060-015-2012-x","article-title":"Dexamethasone alone and in combination with desipramine, phenytoin, valproic acid or levetiracetam interferes with 5-ALA-mediated PpIX production and cellular retention in glioblastoma cells","volume":"127","author":"Lawrence","year":"2016","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.prp.2024.155636_bib190","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00947","article-title":"NY-ESO-1 based immunotherapy of cancer: current perspectives","volume":"9","author":"Thomas","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib191","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11060-008-9732-0","article-title":"Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2\u2032-deoxycytidine in glioma cells","volume":"92","author":"Oi","year":"2009","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.prp.2024.155636_bib192","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2017.00748","article-title":"Advances in Radiotherapy for Glioblastoma","volume":"8","author":"Mann","year":"2018","journal-title":"Front. Neurol."},{"issue":"4","key":"10.1016\/j.prp.2024.155636_bib193","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4161\/cc.7.4.5405","article-title":"Effect of valproic acid on radiation-induced DNA damage in euchromatic and heterochromatic compartments","volume":"7","author":"Harikrishnan","year":"2008","journal-title":"Cell Cycle"},{"issue":"26","key":"10.1016\/j.prp.2024.155636_bib194","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1200\/JCO.2007.11.6202","article-title":"Inhibition of histone deacetylation: a strategy for tumor radiosensitization","volume":"25","author":"Camphausen","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.prp.2024.155636_bib195","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1089\/cbr.2009.0629","article-title":"HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells","volume":"24","author":"Chen","year":"2009","journal-title":"Cancer Biotherapy Radiopharm."},{"issue":"17","key":"10.1016\/j.prp.2024.155636_bib196","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1158\/1078-0432.CCR-08-0643","article-title":"Postradiation sensitization of the histone deacetylase inhibitor valproic acid","volume":"14","author":"Chinnaiyan","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib197","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/ijc.20774","article-title":"Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid","volume":"114","author":"Camphausen","year":"2005","journal-title":"Int. J. Cancer"},{"issue":"2, Part B","key":"10.1016\/j.prp.2024.155636_bib198","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.canlet.2014.09.049","article-title":"DNA damage response and anti-apoptotic proteins predict radiosensitization efficacy of HDAC inhibitors SAHA and LBH589 in patient-derived glioblastoma cells","volume":"356","author":"Berghauser Pont","year":"2015","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.prp.2024.155636_bib199","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.tranon.2016.12.011","article-title":"Dual functional mesoporous silicon nanoparticles enhance the radiosensitivity of VPA in glioblastoma","volume":"10","author":"Zhang","year":"2017","journal-title":"Transl. Oncol."},{"issue":"14","key":"10.1016\/j.prp.2024.155636_bib200","doi-asserted-by":"crossref","first-page":"5859","DOI":"10.1158\/0008-5472.CAN-07-6327","article-title":"Inhibition of glycogen synthase kinase 3\u03b2 attenuates neurocognitive dysfunction resulting from cranial irradiation","volume":"68","author":"Thotala","year":"2008","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.prp.2024.155636_bib201","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/nop\/npy009","article-title":"Late toxicity in long-term survivors from a phase 2 study of concurrent radiation therapy, temozolomide and valproic acid for newly diagnosed glioblastoma","volume":"5","author":"Krauze","year":"2018","journal-title":"Neuro-Oncol. Pract."},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib202","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00228-016-2167-1","article-title":"Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma","volume":"73","author":"Watanabe","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"14","key":"10.1016\/j.prp.2024.155636_bib203","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.3390\/ijms21144915","article-title":"Targeting Wnt\/\u03b2-catenin pathway for developing therapies for hair loss","volume":"21","author":"Choi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.prp.2024.155636_bib204","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1586\/14737175.2015.1051968","article-title":"The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence","volume":"15","author":"Auffinger","year":"2015","journal-title":"Expert Rev. Neurother."},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib205","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.trecan.2020.01.009","article-title":"Glioblastoma stem cells: driving resilience through chaos","volume":"6","author":"Prager","year":"2020","journal-title":"Trends Cancer"},{"issue":"2","key":"10.1016\/j.prp.2024.155636_bib206","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00280-020-04109-w","article-title":"Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells","volume":"86","author":"Reddy","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"7","key":"10.1016\/j.prp.2024.155636_bib207","first-page":"2407","article-title":"Synergistic killing of glioblastoma stem-like cells by bortezomib and hdac inhibitors","volume":"32","author":"Asklund","year":"2012","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib208","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12031-014-0329-0","article-title":"The Effects of Histone Deacetylase Inhibitors on Glioblastoma-Derived Stem Cells","volume":"55","author":"Alvarez","year":"2015","journal-title":"J. Mol. Neurosci."},{"issue":"5","key":"10.1016\/j.prp.2024.155636_bib209","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1074\/jbc.M113.527754","article-title":"Down-modulation of SEL1L, an Unfolded protein response and endoplasmic reticulum-associated degradation protein, sensitizes glioma stem cells to the cytotoxic effect of valproic acid","volume":"289","author":"Cattaneo","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.prp.2024.155636_bib210","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.bcp.2012.09.012","article-title":"Pharmacological targeting of endoplasmic reticulum stress signaling in cancer","volume":"85","author":"Sch\u00f6nthal","year":"2013","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.prp.2024.155636_bib211","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.surg.2008.08.027","article-title":"Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells","volume":"144","author":"Adler","year":"2008","journal-title":"Surgery"},{"issue":"8","key":"10.1016\/j.prp.2024.155636_bib212","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1634\/theoncologist.12-8-942","article-title":"Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells","volume":"12","author":"Greenblatt","year":"2007","journal-title":"oncologist"},{"issue":"4","key":"10.1016\/j.prp.2024.155636_bib213","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/sj.bjc.6602309","article-title":"Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells","volume":"92","author":"Stockhausen","year":"2005","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.prp.2024.155636_bib214","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3390\/genes9110522","article-title":"Valproic acid inhibits proliferation and reduces invasiveness in glioma stem cells through Wnt\/\u03b2 catenin signalling activation","volume":"9","author":"Riva","year":"2018","journal-title":"Genes"},{"issue":"5","key":"10.1016\/j.prp.2024.155636_bib215","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.3892\/or.2016.4665","article-title":"Epigenetic targeting of glioma stem cells: Short-term and long-term treatments with valproic acid modulate DNA methylation and differentiation behavior, but not temozolomide sensitivity","volume":"35","author":"Riva","year":"2016","journal-title":"Oncol. Rep."},{"issue":"5","key":"10.1016\/j.prp.2024.155636_bib216","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ijrobp.2015.04.038","article-title":"A Phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma","volume":"92","author":"Krauze","year":"2015","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"key":"10.1016\/j.prp.2024.155636_bib217","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.clineuro.2018.09.019","article-title":"The survival effect of valproic acid in glioblastoma and its current trend: a systematic review and meta-analysis","volume":"174","author":"Lu","year":"2018","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"11","key":"10.1016\/j.prp.2024.155636_bib218","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1159\/000526327","article-title":"Administration of Valproic Acid Improves the Survival of Patients with Glioma Treated with Postoperative Radiotherapy","volume":"45","author":"Wang","year":"2022","journal-title":"Oncol. Res. Treat."},{"issue":"24","key":"10.1016\/j.prp.2024.155636_bib219","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1556\/650.2021.32110","article-title":"Supplementary valproate therapy for glioma patients: An alternative opportunity to enhance the efficiency of radio-chemotherapy","volume":"162","author":"Mezei","year":"2021","journal-title":"Orv. Hetil."},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib220","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ijrobp.2013.02.012","article-title":"Valproic Acid Use During Radiation Therapy for Glioblastoma Associated With Improved Survival","volume":"86","author":"Barker","year":"2013","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"issue":"7","key":"10.1016\/j.prp.2024.155636_bib221","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/neuonc\/not057","article-title":"Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme","volume":"15","author":"Kerkhof","year":"2013","journal-title":"Neuro-Oncol."},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib222","article-title":"The addition of Valproic acid to concurrent radiation therapy and temozolomide improves patient outcome: a Correlative analysis of RTOG 0525, SEER and a Phase II NCI trial","volume":"5","author":"Krauze","year":"2020","journal-title":"Cancer Stud. Ther."},{"issue":"12","key":"10.1016\/j.prp.2024.155636_bib223","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1212\/WNL.0b013e31822f02e1","article-title":"Prolonged survival with valproic acid use in the EORTC\/NCIC temozolomide trial for glioblastoma","volume":"77","author":"Weller","year":"2011","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib224","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s11060-016-2054-8","article-title":"Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II\/III gliomas treated with temozolomide","volume":"127","author":"Redjal","year":"2016","journal-title":"J. Neuro-Oncol."},{"issue":"10","key":"10.1016\/j.prp.2024.155636_bib225","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.seizure.2014.06.015","article-title":"Survival analysis for valproic acid use in adult glioblastoma multiforme: A meta-analysis of individual patient data and a systematic review","volume":"23","author":"Yuan","year":"2014","journal-title":"Seizure"},{"issue":"4","key":"10.1016\/j.prp.2024.155636_bib226","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3171\/2012.10.JNS12169","article-title":"Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme","volume":"118","author":"Guthrie","year":"2013","journal-title":"J. Neurosurg."},{"issue":"28","key":"10.1016\/j.prp.2024.155636_bib227","article-title":"Effect of valproic acid on overall survival in patients with high-grade gliomas undergoing temozolomide: a nationwide population-based cohort study in Taiwan","volume":"99","author":"Kuo","year":"2020","journal-title":"Med. (Baltim. )"},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib228","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/nop\/npac078","article-title":"Valproic acid as a radio-sensitizer in glioma: a systematic review and meta-analysis","volume":"10","author":"Sullivan","year":"2023","journal-title":"Neuro-Oncol. Pract."},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib229","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11060-016-2191-0","article-title":"Does the choice of antiepileptic drug affect survival in glioblastoma patients?","volume":"129","author":"Knudsen-Baas","year":"2016","journal-title":"J. Neuro-Oncol."},{"issue":"7","key":"10.1016\/j.prp.2024.155636_bib230","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1200\/JCO.2015.63.6563","article-title":"Does valproic acid or levetiracetam improve survival in glioblastoma? a pooled analysis of prospective clinical trials in newly diagnosed glioblastoma","volume":"34","author":"Happold","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.prp.2024.155636_bib231","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225599","article-title":"Effect of anti-epileptic drugs on the survival of patients with glioblastoma multiforme: A retrospective, single-center study","volume":"14","author":"Ryu","year":"2019","journal-title":"PLOS ONE"},{"issue":"6","key":"10.1016\/j.prp.2024.155636_bib232","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28283","article-title":"A phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high-grade glioma","volume":"67","author":"Su","year":"2020","journal-title":"Pedia Blood Cancer"},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib233","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3109\/02688697.2011.638996","article-title":"Effect of valproic acid on the outcome of glioblastoma multiforme","volume":"26","author":"Tsai","year":"2012","journal-title":"Br. J. Neurosurg."},{"key":"10.1016\/j.prp.2024.155636_bib234","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jconrel.2018.12.049","article-title":"Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis","volume":"295","author":"Costa","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.prp.2024.155636_bib235","first-page":"369","article-title":"The therapeutic and neuroprotective effects of an antiepileptic drug valproic acid in glioma patients","volume":"258","author":"Li","year":"2020","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.prp.2024.155636_bib236","article-title":"The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines","author":"Organization","year":"2021","journal-title":"2021 (Incl. 22nd WHO Model List Essent. Med. 8th WHO Model List Essent. Med. Child. )"},{"issue":"4C","key":"10.1016\/j.prp.2024.155636_bib237","first-page":"2437","article-title":"Influence of valproic acid on outcome of high-grade gliomas in children","volume":"28","author":"Masoudi","year":"2008","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.prp.2024.155636_bib238","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00415-014-7552-z","article-title":"Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study","volume":"262","author":"Tinchon","year":"2015","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.prp.2024.155636_bib239","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2174\/0929867329666220707103525","article-title":"The potential therapeutic impact of metformin in glioblastoma multiforme","volume":"30","author":"Sanati","year":"2023","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.prp.2024.155636_bib240","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/bs.pmbts.2023.12.001","article-title":"Application of RNA-based therapeutics in glioma: A review","volume":"204","author":"Sanati","year":"2023","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"issue":"8","key":"10.1016\/j.prp.2024.155636_bib241","doi-asserted-by":"crossref","first-page":"564","DOI":"10.2174\/1389200221666200714101038","article-title":"The current state of potential therapeutic modalities for glioblastoma multiforme: a clinical review","volume":"21","author":"Mohtashami","year":"2020","journal-title":"Curr. Drug Metab."},{"issue":"5","key":"10.1016\/j.prp.2024.155636_bib242","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/biof.1756","article-title":"Zerumbone, a ginger sesquiterpene, inhibits migration, invasion, and metastatic behavior of human malignant glioblastoma multiforme in vitro","volume":"47","author":"Jalili-Nik","year":"2021","journal-title":"BioFactors"},{"issue":"18","key":"10.1016\/j.prp.2024.155636_bib243","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.2174\/1389557520666200807133659","article-title":"Modulation of calcium signaling in glioblastoma multiforme: a therapeutic promise for natural products","volume":"20","author":"Afshari","year":"2020","journal-title":"Mini Rev. Med. Chem."},{"issue":"24","key":"10.1016\/j.prp.2024.155636_bib244","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.2174\/0929867328666210113165805","article-title":"Neurokinin-1 receptor (NK-1R) antagonists: potential targets in the treatment of glioblastoma multiforme","volume":"28","author":"Afshari","year":"2021","journal-title":"Curr. Med. Chem."},{"issue":"26","key":"10.1016\/j.prp.2024.155636_bib245","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.2174\/0929867329666220224112811","article-title":"Anticancer mechanisms of Berberine: a good choice for glioblastoma multiforme therapy","volume":"29","author":"Bibak","year":"2022","journal-title":"Curr. Med. Chem."},{"issue":"11","key":"10.1016\/j.prp.2024.155636_bib246","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1111\/jphp.12800","article-title":"Characterisation, in-vitro and in-vivo evaluation of valproic acid-loaded nanoemulsion for improved brain bioavailability","volume":"69","author":"Tan","year":"2017","journal-title":"J. Pharm. Pharmacol."},{"issue":"9","key":"10.1016\/j.prp.2024.155636_bib247","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1211\/0022357001774958","article-title":"Influence of Nanoparticles on the Brain-to-serum Distribution and the Metabolism of Valproic Acid in Mice","volume":"52","author":"Darius","year":"2000","journal-title":"J. Pharm. Pharmacol."},{"issue":"null","key":"10.1016\/j.prp.2024.155636_bib248","first-page":"363","article-title":"Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model","volume":"6","author":"Eskandari","year":"2011","journal-title":"Int. J. Nanomed."},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib249","article-title":"Study of valproic acid liposomes for delivery into the brain through an intranasal route","volume":"8","author":"Jufri","year":"2022","journal-title":"Heliyon"},{"issue":"3","key":"10.1016\/j.prp.2024.155636_bib250","doi-asserted-by":"crossref","first-page":"31","DOI":"10.5530\/ijper.47.3.6","article-title":"Development of valproic acid niosomal in situ nasal gel formulation for epilepsy","volume":"47","author":"Chaudhari","year":"2013","journal-title":"Indian J. Pharm. Educ. Res."},{"issue":"11","key":"10.1016\/j.prp.2024.155636_bib251","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/iub.1445","article-title":"Valproic acid sensitizes human glioma cells to gefitinib-induced autophagy","volume":"67","author":"Chang","year":"2015","journal-title":"IUBMB Life"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824005478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824005478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T02:06:23Z","timestamp":1732845983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033824005478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":251,"alternative-id":["S0344033824005478"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2024.155636","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent update on anti-tumor mechanisms of valproic acid in glioblastoma multiforme","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2024.155636","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"155636"}}